October represents the month of liver recognition, marked as a time when many countries look back at incredibly resilient yet vulnerable organs. Liver disease is an increasing problem around the world, but in Western countries, more than four times more deaths have increased in the UK over the past 50 years.1. This is especially relevant to statistics when deaths from other illnesses are steadily falling.
Sadly, the majority of liver disease deaths could have been prevented by lifestyle changes alone, if they were diagnosed early enough. By the time symptoms appear, many patients are in advanced stages and have acquired the label “silent killer” for these diseases. With more people than ever at risk for liver-related diseases, it is good to confirm that increased conditions such as fatty liver disease (MASLD) associated with metabolic dysfunction have spread awareness of increased symptoms of metabolic dysfunction-associated fatty liver disease (MAFLD), type 2 diabetes, and ALLIVERIVERISE AR AR AR spawning.
Liver insulin resistance is a common factor in many of these conditions. Over time, liver cells can stop the proper response to the hormone insulin, which supports blood glucose regulation, contributing to type 2 diabetes and fat accumulation in the liver. Without a diagnosis, the fatty liver can become inflamed and become fibrous, leading to severe conditions including liver failure and cancer.
Metabolic disorders in humans are complex, multifactorial and difficult to study. In the past, researchers had to select animal models. Animal models do not adequately reflect the metabolism of the human liver (for example, rodents have catabolism, whereas humans have a metabolism of assimilation), and simple cell cultures lacking the complexity of actual organs or tissues. Thankfully, new innovations are changing the game, bringing new hope for the future of liver health, in the form of predictive, human-related research tools that can be used to understand disease and accelerate the development of new therapies.
Human liver is cultivated in a laboratory to model disease
Recent joint pre-prints between the pioneering Novo Nordisk and Organ-on-a-Chip (OOC) at Massachusetts Institute of Technology (MIT)2. These miniaturized laboratory-grown organs were perfused by cell culture medium, mimicking blood flow and maintaining physiology and function for several weeks at a time.
In this study, the authors exposed liver micro-qualities to specific metabolic stressors to simulate poor diet and metabolic overload. In humans, drivers of progressive liver insulin resistance interact in complex ways and are traditionally difficult to study, but liver MPS microidery provides an ideal test system for sequestering and understanding their effects under controlled conditions:
- Normal vs. High insulin (To mimic hyperinsulinemia, a characteristic of early diabetes)
- Normal vs. High glucose (To simulate hyperglycemia)
- Normal vs. Fatty acid rise (To reflect excess dietary fat)
Using this model, we found that high insulin levels of liver microbes caused insulin resistance in just one week, and when high glucose and fatty acids were combined, the insulin resistance phenotype was worsened. Molecular level investigations showed that these conditions effectively “rewire” gene expression patterns, disrupt insulin signaling, and fat and bile acids accumulate within hepatocytes. In particular, when metabolic stressors were removed, many of these adverse effects were partially reversed, as seen in patients with improved diet and exercise levels.
The findings showed that:
- Liver MP can model insulin resistance in human liver.
- Individual synergistic contributions of hyperinsulinemia, hyperglycemia, and lipid elevation can be analyzed in disease pathology in vitro.
- Liver MP can facilitate testing for new therapeutic agents aimed at reversing or preventing insulin resistance.
Furthermore, the reversibility of liver lawmakers is clearly in line with advice from healthcare workers that lifestyle changes to eliminate poor diets and metabolic stressors can reverse early stage changes.
Filling the translation gap from lab to clinic with machine learning
Reproducing human diseases in the laboratory is not the end of this transformational journey. Since last year's Liver Awareness Month, MIT researchers have gone a step further to bridge the translation gap between laboratory data and clinical outcomes. Recent Print Publications We demonstrate the use of systems biology and machine learning frameworks to map how experimental conditions in the MPS model are related to human liver disease biology. 3
The authors describe the presentation as a case study of the use of the MAFLD model studied using liver MPS. liv2trans (potentiality) in vitro In in vivo Translation) Machine learning framework. They demonstrate the potential of a framework to determine the optimal experimental conditions for determining the optimal experimental conditions such as growth factors, cytokines, and matrix proteins.
This study found signaling of TGF-β, JAK-STAT, ANDROGEN, and EGFR, which was more representative when engineered in the model. in vivo The disease process. author Expect this approach to help:
- Address the question of how complex the MPS model should be in order to accurately replicate the disease of interest.
- Accelerate the process of in vitro Model design.
- Strengthen the Translationability of MPS-generated data in vivo Human context.
Why is this new research important?
Liver Awareness Month is about recognizing and acknowledging the perceptions of serious healthcare challenges associated with this critical organ disease, but should celebrate innovation from the research community. Ultimately, only through collaboration can we bring about a future where we can effectively reduce the global impact of liver disease.
The above studies show that human liver disease research is entering an exciting new era. in vitro Models are increasingly human-related, allowing researchers to study disease onset and mechanisms more accurately, identify opportunities for intervention, and predict outcomes for new therapeutics.
As the disparity between laboratory-based data and clinical outcomes narrows through the application of the A-Optimized MPS model, the theoretical risk of failed clinical trials decreases as well. In relation to strengthening public education efforts, there is a new optimism to achieve a pivotal moment that predicts, prevents, and reverses liver disease and reduces its prevalence.
reference
1. Addressing liver diseases in Williams R, Aspineol R, Belis M, and others: A blueprint for achieving healthcare excellence and reducing early mortality due to lifestyle issues of excessive consumption of alcohol, obesity and viral hepatitis. Rancet. 2014; 384 (9958): 1953-1997. doi: 10.1016/S0140-6736(14)61838-9
2. Microphysiological models of progressive human liver insulin resistance, including Hellen DJ, Ungerleider J, and Tevonian E. biorxiv. Preprint was posted online on January 8, 2025: 2025.01.08.631261. doi: 10.1101/2025.01.08.631261
3. Cadavid JL, Meimetis N, Griffith LG, Lauffenburger DA. Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of microphysiological systems. biorxiv. Preprint was posted online on January 22, 2025: 2025.01.17.633624. doi:10.1101/2025.01.17.633624
This article is based on findings that have not yet been peer-reviewed. Therefore, the results should be considered preliminary and interpreted as such. Investigating the role of the peer review process in research here. For more information, please contact the source quoted.
